Molecular screening of gastric cancer by proteome analysis

European Journal of Gastroenterology and Hepatology

Volumn 18, Issue 8, 2006, Pages 847-853

  Ebert, Matthias P A ^a   Röcken, Christoph ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Universitätsmedizin   (Germany)

Author keywords

Diagnosis; Gastric; Proteome; Screening; Serum; Stomach

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER; UVOMORULIN;

CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; CARCINOGENESIS; DIAGNOSTIC PROCEDURE; EARLY DIAGNOSIS; HUMAN; IMMUNOLOGY; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; STOMACH CANCER;

EARLY DIAGNOSIS; HUMANS; NEOPLASM PROTEINS; PROTEOMICS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33745855873     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200608000-00007     Document Type: Review

References (50)

1. Fuchs CJ, Mayer RJ. Gastric carcinoma. N Engl J Med 1995; 333:32-41.
2. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process-first American Cancer Society Award Lecture on cancer epidemiology and prevention. Cancer Res 1992; 52:6735-6740.
3. Ebert MPA, Malfertheiner P. Pathogenesis of sporadic and familial gastric cancer - implications for clinical management and cancer prevention. Aliment Pharmacol Ther 2002; 16:1059-1066.
4. Götze T, Schütte K, Röcken C, Malfertheiner P, Ebert MP. Recent developments in chemotherapy of advanced gastric cancer. Dig Dis 2004; 22:360-366.
5. Sumiyama K, Kaise M, Nakayoshi T, Kato M, Mashiko T, Uchiyama Y, et al. Combined use of a magnifying endoscope with a narrow band imaging system and a multibending endoscope for en bloc EMR of early stage gastric cancer. Gastrointest Endosc 2004; 60:79-84.
6. Ohkawa A, Miwa H, Namihisa A, Kobayashi O, Nakaniwa N, Ohkusa T, et al. Diagnostic performance of light-induced fluorescence endoscopy for gastric neoplasms. Endoscopy 2004; 36:515-521.
7. Carpelan-Holmstrom M, Louhimo J, Stenman UH, Alfthan H, Jarvinen H, Haglund C. CEA, CA 242, CA 19-9, CA 72-4 and hCGbeta in the diagnosis of recurrent colorectal cancer. Tumour Biol 2004; 25:228-234.
8. Kosugi S, Nishimaki T, Kanda T, Nakagawa S, Ohashi M, Hatakeyama K. Clinical significance of serum carcinoembryonic antigen, carbohydrate antigen 19-9, and squamous cell carcinoma antigen levels in esophageal cancer patients. World J Surg 2004; 28:680-685.
9. Yuen MF, Lai CL. Serological markers of liver cancer. Best Pract Res Clin Gastroenterol 2005; 19:91-99.
10. Weinmann S, Richert-Boe KE, Van Den Eeden SK, Enger SM, Rybicki BA, Shapiro JA, et al. Screening by prostate-specific antigen and digital rectal examination in relation to prostate cancer mortality: a case-control study. Epidemiology 2005; 16:367-376.
11. Marrelli D, Roviello F, de Stefano A, Farnetani M, Garosi L, Messano A, et al. Prognostic significance of CEA, Ca 19-9 and Ca 72-4 preoperative serum levels in gastric carcinoma. Oncology 1999; 57:55-62.
12. Nakajima K, Ochiai T, Suzuki T, Shimada H, Hayashi H, Yasumoto A, et al. Impact of preoperative serum CEA, Ca 19-9 and alpha fetoprotein levels in gastric cancer patients. Tumor Biol 1998; 19:464-469.
13. Istigami S, Natsugoe S, Hokita S, Che X, Tokuda K, Nakajo A, et al. Clinical importance of preoperative carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer. J Clin Gastroenterol 2001; 32:41-44.
14. Tocchi A, Costa G, Lepre L, Lotta G, Mazzoni G, Cianetti A, et al. The role of serum and gastric juice levels of carcinoembryonic antigen, Ca 19-9 and Ca 72-4 in patients with gastric cancer. J Cancer Res Clin Oncol 1998; 124:450-455.
15. Gaspar MJ, Arribas I, Coca MC, Diez-Alonso M. Prognostic value of carcinoembryonic antigen, Ca 19-9 and Ca 72-4 in gastric carcinoma. Tumor Biol 2001; 22:318-322.
16. Marrelli D, Pinto E, De Stefano A, Farnetani M, Garosi L, Roviello F. Clinical utility of CEA, Ca 19-9 and Ca 72-4 in the follow-up of patients with resectable gastric cancer. Am J Surg 2001; 181:16-19.
17. Johnson VG, Schlom J, Paterson AJ, Bennet J, Magnani JL, Cocher D. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res 1986; 46:850-857.
18. Tahara E, Semba S, Tahara H. Molecular biological observations in gastric cancer. Semin Oncol 1996; 23:307-315.
19. An C, Choi IS, Yao JC, Worah S, Xie K, Mansfield PF, et al. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res 2005; 11:656-663.
20. Keller G, Vogelsang H, Becker I. Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin gene mutation. Am J Pathol 1999; 155:337-342.
21. Si HX, Tsao SW, Lam KY. E-cadherin expression is commonly downregulated by CpG island hypermethylation in esophageal carcinoma cells. Cancer Lett 2001; 173:71-78.
22. Yu J, Ebert MPA, Miehlke S, Rost H, Lendeckel U, Leodolter A, et al. α-Catenin expression is decreased in human gastric cancers and in the gastric mucosa of first degree relatives. Gut 2000; 46:639-644.
23. Ebert MPA, Fei G, Kahmann S, Muller O, Yu J, Sung JJ, et al. Increased beta-catenin mRNA levels and mutational alterations of the APC and beta-catenin gene are present in intestinal-type gastric cancer. Carcinogenesis 2002; 23:87-91.
24. Yu J, Leung WK, Ebert MP, Leong RW, Tse PC, Chan MW, et al. Absence of cyclin D2 expression is associated with promoter hypermethylation in gastric cancer. Br J Cancer 2003; 88:1560-1565.
25. Geddert H, Kiel S, Iskender E, Florl AR, Krieg T, Vossen S, et al. Correlation of hMLH1 and HPP1 hypermethylation in gastric, but not in esophageal and cardiac adenocarcinoma. Int J Cancer 2004; 110:208-211.
26. Sarbia M, Geddert H, Klump B, Kiel S, Iskender E, Gabbert HE. Hypermethylation of tumor suppressor genes (p16INK4A, p14ARF and APC) in adenocarcinomas of the upper gastrointestinal tract. Int J Cancer 2004; 111:224-228.
27. Ichikawa D, Koike H, Ikoma H, Ikoma D, Tani N, Otsuji E, et al. Detection of aberrant methylation as a tumor marker in serum of patients with gastric cancer. Anticancer Res 2004; 24:2477-2481.
28. Kanyama Y, Hibi K, Nakayama H, Kodera Y, Ito K, Akiyama S, et al. Detection of p16 promoter hypermethylation in serum of gastric cancer patients. Cancer Sci 2003; 94:418-420.
29. Koike H, Ichikawa D, Ikoma H, Otsuji E, Kitamura K, Yamagishi H. Comparison of methylation-specific polymerase chain reaction (MSP) with reverse transcriptase-polymerase chain reaction (RT-PCR) in peripheral blood of gastric cancer patients. J Surg Oncol 2004; 87:182-186.
30. Chan AO, Chu KM, Lam SK, Wong BC, Kwok KF, Law S, et al. Soluble E-cadherin is an independent pretherapeutic factor for long-term survival in gastric cancer. J Clin Oncol 2003; 21:2288-2293.
31. Juhasz M, Ebert MP, Schulz HU, Rocken C, Molnar B, Tulassay Z, et al. Dual role of serum soluble E-cadherin as a biological marker of metastatic development in gastric cancer. Scand J Gastroenterol 2003; 38:850-855.
32. Gofuku J, Shiozaki H, Doki Y. Characterization of soluble E-cadherin as a disease marker in gastric cancer patients. Br J Cancer 1998; 78: 1095-1101.
33. Lee TL, Leung WK, Chan MW, Ng EK, Tong JH, Lo KW, et al. Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. Clin Cancer Res 2002; 8:1761-1766.
34. Ohta M, Konno H, Tanaka T, Baba M, Kamiya K, Syouji T, et al. The significance of circulating vascular endothelial growth factor (VEGF) protein in gastric cancer. Cancer Lett 2003; 192:215-225.
35. Karayiannakis AJ, Syrigos KN, Polychronidis A, Zbar A, Kouraklis G, Simopoulos C, et al. Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann Surg 2002; 236:37-42.
36. Maruo Y, Gochi A, Kaihara A, Shimamura H, Yamada T, Tanaka N, et al. ICAM-1 expression and the soluble ICAM-1 level for evaluating the metastatic potential of gastric cancer. Int J Cancer 2002; 100:486-490.
37. Tanaka K, Miki C, Wakuda R, Kobayashi M, Tonouchi H, Kusunoki M. Circulating level of hepatocyte growth factor as a useful tumor marker in patients with early-stage gastric carcinoma. Scand J Gastroenterol 2004; 39:754-760.
38. Ebert MP, Kruger S, Fogeron ML, Lamer S, Chen J, Pross M, et al. Overexpression of cathepsin B in gastric cancer identified by proteome analysis. Proteomics 2005; 5:1693-1704.
39. Varis K, Sipponen P, Laxen F, Samloff IM, Huttunen JK, Taylor PR, et al. Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dysplasia. Helsinki Gastritis Study Group. Scand J Gastroenterol 2000; 35:950-956.
40. Miki K, Morita M, Sasajima M, Hoshina R, Kanda E, Urita Y. Usefulness of gastric cancer screening using the serum pepsinogen test method. Am J Gastroenterol 2003; 98:735-739.
41. Rocken C, Ebert MP, Roessner A. Proteomics in pathology, research and practice. Pathol Res Pract 2004; 200:69-82.
42. Issaq HJ, Veenstra TD, Conrads TP, Felschow D. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Comm 2002; 292:587-592.
43. Rosty C, Christa L, Kuzdzal S, Baldwin WM, Zahurak ML, Carnot F, et al. Identification of hepatocarcinoma-intestine-pancreas pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res 2002; 62:1868-1875.
44. Vlahou A, Schellhammer PF, Mandrinos S, Patel K, Kondylis FI, Gong L, et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 2001; 158:1491-1502.
45. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002; 62:3609-3614.
46. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359:572-577.
47. Qu Y, Adam BL, Yasui Y, Ward MD, Cazares LH, Schellhammer PF, et al. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 2002; 48:1835-1843.
48. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002; 48:1296-1304.
49. Ebert M, Meuer J, Wiemer J, Schulz HU, Reymond M, Malfertheiner P, et al. Identification of patients with gastric cancer by serum protein profiling. J Proteome Res 2004; 4:1261-1266.
50. Ebert MP, Meuer J, Lamer S, Malfertheiner P, Röcken C, Buschmann T, et al. Identification of the thrombin light chain A as the single best mass for differentiation of gastric cancer patients from individuals with dyspepsia by proteome analysis. J Proteome Res 2005; 4:586-590.